Trial Profile
Risk of cardiac-related hospitalization in multiple myeloma patients treated with carfilzomib versus non-carfilzomib in the United States
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jun 2018
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 25 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology